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Monoclonal antibodies are a commercially successful
class of drug molecules and there are now a growing
number of antibodies coupled to toxic payloads, which
demonstrate clinical efﬁcacy. Determining the precise
epitope of therapeutic antibodies is beneﬁcial in under-
standing the structure–activity relationship of the drug,
but in many cases is not done due to the structural com-
plexity of, in particular, conformational protein epitopes.
Using the immunotoxin CAT-8015 as a test case, this
study demonstrates that a new methodology, hybrid b-
lactamase display, can be employed to elucidate a
complex epitope on CD22. Following insertion of random
CD22 gene fragments into a permissive site within b-lac-
tamase, proteins expressed in Escherichia coli were ﬁrst
screened for correct folding by resistance to ampicillin
and then selected by phage display for afﬁnity to CAT-
8015. The optimal protein region recognised by CAT-
8015 could then be used as a tool for ﬁne epitope
mapping, using alanine-scanning analysis, demonstrating
that this technology is well suited to the rapid characteris-
ation of antibody epitopes.
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Introduction
The elucidation of an antibody epitope is a key step in under-
standing the relationship between structure and function at
the antigen–antibody interface. This can enable the future
isolation of higher afﬁnity, more potent, antibody analogues
and also has the potential to enable design of smaller anti-
body mimetics, peptides and even small molecules, which
can mimic the antibody-binding mechanism and interact
with the same epitope region. Perhaps more importantly,
epitope studies can shed light on how the structure of the
target antigen determines its natural biological function.
While an X-ray co-crystal structure of the antigen–
antibody complex remains the gold standard of epitope deter-
mination, it is not a widely available technology and is not
always feasible due to the difﬁculty of obtaining high con-
centrations of good-quality proteins and also in ﬁnding the
correct conditions to produce diffracting crystals. In the
absence of a crystal complex, hydrogen/deuterium exchange
(e.g. DXMS, H/D-Ex, etc.) is an attractive option.
Unfortunately, these techniques require large quantities of
soluble, homogenous, highly puriﬁed and stable antigens and
may run the risk that the puriﬁed recombinant antigen does
not closely resemble the native protein.
Of the many other epitope mapping techniques which
exist, all are faced with the same problem which is the ﬁne
mapping of conformational epitopes and the attribution of
the key amino acids on the 3D structure of the antigen when
one is available. For instance, epitope mapping on a peptide
microarray allows the study of thousands of speciﬁc-binding
sequences in a single experiment (Reineke et al., 2001). This
technique is very efﬁcient for mapping of linear epitopes and
the CLIPSTM technology developed by Pepscan, which
stabilises peptides in biologically relevant structures, can
give some informative results about the characterisation of
conformational epitopes (Timmerman et al., 2007).
Unfortunately, these approaches are complex with regard to
the vast combinations of peptides to be analysed before
ﬁnding out the appropriate conformation.
The screening of phage libraries displaying random pep-
tides has had limited impact on the mapping of confor-
mational epitopes because the selected peptides are regarded
as mimotopes of the genuine epitope of the antibody’s inter-
acting antigen. Typically, an algorithm is used to align a set
of query peptides from the phage display process onto the
solved structure of the antigen. Following a clustering step,
which combines the most signiﬁcant matches, only one pre-
dicted epitope is inferred in the better cases (Mayrose et al.,
2007). If no crystal structure is available, the result of this
approach is typically a consensus mimotope sequence, which
is difﬁcult to locate over a primary amino acid sequence.
Methods based on mutagenesis of the target antigen, in
particular combinatorial alanine scanning (Weiss et al.,
2000), are attractive due to their relative speed and the
precise analysis of individual side-chain contributions to the
binding energy. However, such methods do require signiﬁ-
cant mutagenesis efforts when used to probe the entire
surface area of a large target antigen. To reduce the muta-
genesis burden, one may employ a domain deletion approach
to focus the epitope search (Lacal and Aaronson, 1986).
Such methods can be successful but it is worth noting that
domain deletion experiments measure a negative outcome,
i.e. the loss of binding, which could be explained by other
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quaternary structure or the introduction of an aggregation
liability.
In this context, the expression of random antigen frag-
ments into a highly-permissive and solvent-exposed loop of
the Bacillus licheniformis b-lactamase BlaP and the screen-
ing of these hybrid b-lactamases using phage display offers
several beneﬁts. First, it has been demonstrated that the use
of BlaP as a protein carrier makes easier the expression of
protein domains known to be insoluble or difﬁcult to express
and that the protein carrier confers enough conformational
ﬂexibility to the inserts for refolding and interacting with
their native ligands (Chevigne et al., 2007; Vandevenne
et al., 2007, 2008; Ruth et al., 2008). Next, the random inser-
tion of fragments of the target gene into the blaP gene
allows a large number of protein fragments with different
sizes to be expressed from the same polypeptide region. As a
result, this region can adopt a large number of different
folds. This feature allows the generation of epitope libraries
which do not correspond to mimotopes because they are
directly related to the nucleotide sequence of the antigen. By
alteration of the fragment sizes, the library can be made
more representative of linear or conformational epitopes. In
addition, this method can be viewed as an original method-
ology to expose cryptic epitopes when these are not accessi-
ble in the native antigen. In this procedure, the b-lactam
resistance conferred to Escherichia coli infected with phages
expressing soluble and functional hybrid b-lactamases is
pivotal because it allows a positive selection of phages
during the phage library construction and provides an easy
method to measure the enrichment of the phage library
during successive rounds of biopanning. Moreover, the fact
that the epitope is selected as a bifunctional hybrid protein,
which associates an epitope with a speciﬁc and efﬁcient
enzymatic activity, allows rapid characterisation of the
antigen–antibody interaction.
In this case study, we applied the hybrid b-lactamase
display method to identify the epitope of the anti-CD22
immunotoxin CAT-8015. Therapeutically, CD22 is of inter-
est because it is a speciﬁc marker present on the cell surface
of malignant B cells and is rapidly internalised upon
binding, making it an appealing target for an antibody drug
conjugate or immunotoxin approach (Clark, 1993; Du et al.,
2008). CAT-8015 is an immunotoxin which combines a
CD22-speciﬁc antibody variable fragment (Fv) with a
Pseudomonas exotoxin A (PE38) payload and has demon-
strated noteworthy clinical activity in chronic lymphocytic
leukaemia (CLL), hairy cell leukaemia (HCL) (Alderson
et al., 2009) and paediatric acute lymphoblastic leukaemia
(Mussai et al., 2010). It is one of the several anti-CD22 anti-
bodies currently in clinical trials, including epratuzumab
(Dorner et al., 2006) and inotuzumab ozogomicin (Wong
and Dang, 2010).
CD22 itself is a cell surface glycoprotein with multiple,
immunoglobulin (Ig)-like domains within its extracellular
portion. The N-terminal Ig-like V-type domain, which med-
iates sialic acid binding (May et al., 1998), is followed by
varying numbers of Ig-like C2-type domains (Crocker and
Varki, 2001a,b). No structural data exist for CD22 and rela-
tively little structural information is available for related
family members, due to their high levels of glycosylation.
However, some general information exists on the epitope of
anti-CD22 antibodies, including the predecessors of
CAT-8015, epratuzumab and inotuzumab. This information
has arisen from antibody competition-binding studies and the
binding of antibodies to domain deletion mutants of CD22
and suggests that CAT-8015 and epratuzumab both bind to
the C-like domain 2 while inotuzumab binds to the V-like
domain (Li et al., 1989; Stein et al., 1993; Engel et al., 1995;
DiJoseph et al., 2005). However, such studies do not give the
precise location of the antibody epitopes.
In the present study we were interested to achieve a more
comprehensive epitope mapping analysis of the antibody
CAT-8015 to identify the CD22 residues involved in the
interaction. Random fragments of the human CD22 gene
were cloned into the blaP gene and the bifunctional hybrid
b-lactamases were afﬁnity selected on the antibody
CAT-8015 by phage display. This approach enabled the
identiﬁcation of a CD22 sub-region conferring high afﬁnity
for CAT-8015, which could then be used in an
alanine-scanning study to characterise the key amino acids
involved in binding. These results support the assumption
that the extracellular domains of CD22 could interact
together and participate to form the CAT-8015 epitope.
Materials and methods
Phage display methodology
Preparation of CD22 gene fragments. The gene fragment
encoding the extracellular domain (Asp20 to Arg687) of the
human CD22 protein (CD22, accession number NM_001771;
Wilson et al., 1991) was chemically synthesised to avoid the
use of rare codons; the synthetic gene was optimised accord-
ing to the E.coli codon usage. We also avoided introducing
regions with very high (.80%) or very low (,30%) GC
content, internal TATA boxes, ribosomal entry sites, repeat
sequences and RNA secondary structures. The absence of
RNA secondary structure is of crucial importance because
this parameter governs the intensity and the speciﬁcity of the
signals generated with the epitope array. The gene coding for
the CD22 extracellular domain (CD22ed) was PCR ampliﬁed
using Taq and Pfu DNA polymerase from the synthetic gene,
obviating the need for large-scale puriﬁcation and digestion
of plasmid DNA. The cloning of DNA fragments not related
to the cd22ed is then not possible. The DNAse Shotgun
w
cleavage kit (Novagen) was used on the puriﬁed PCR pro-
ducts to produce random gene fragments ranging from 50- to
1000-bp in length. Four digestions were done in a total
volume of 60 ml in the presence of 0.048 Unit of DNAse and
12.5 mg of PCR products. The digestion reactions were
stopped after 1, 2, 3 or 4 min with 10 mM EDTA. Five
microlitres of each reaction was loaded on agarose gel to
control the range of the DNA fragments. The rest of the
digestions were pooled and successively puriﬁed, repaired
using Pfu polymerase and ﬁnally puriﬁed once more. The
end-repaired gene fragments were dephosphorylated using
calf intestine phosphatase to avoid multiple cloning of
cd22ed fragments into the same vector. All the puriﬁcations
were done with the QIAquick Nucleotide Removal Kit
(Qiagen).
Construction of the fd-Tet BlaP/CD22ed gene-fragments
library. The blaP gene was modiﬁed by introducing a SmaI
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gene fragments. The recombinant blaP-SmaI gene was fused
with the phage pIII gene to generate fd-Tet BlaP/SmaI
(Chevigne et al., 2007). The CD22ed gene fragments were
ligated into the SmaI-digested fd-Tet BlaP/SmaI. The ligation
products was dialysed against water and used to transform
electrocompetent E.coli TG1 (Stratagene). Electrotrans-
formed cells were regenerated in the SOC medium for 1 h at
378C and plated on LB agar medium supplemented with
7.5 mg/ml tetracycline and 5 mg/ml ampicillin.
Phage preparation. The transformants were scraped and sus-
pended in the LB liquid medium supplemented with 7.5 mg/
ml tetracycline and 5 mg/ml ampicillin. Phages were ampli-
ﬁed at 288C for 16 h and recovered from the culture super-
natant by two polyethylene glycol precipitations. After the
ﬁrst precipitation, a ﬁltration through a 0.45-mm ﬁlter was
performed to remove membrane fragments. Phages were sus-
pended in TBS (50 mM Tris, 150 mM NaCl at pH 7.6) and
the phage concentration was estimated by measuring the
absorbance at 265 nm.
Checking the expression of hybrid b-lactamases. The pres-
ence of a cloned CD22ed gene fragment into the blaP gene
was checked by PCR from individual colonies with primers
BlapSmaseq (50-CAGAGTTAAATGAAGTGAATCCGGGT
GAAACTCAGGAT-30) and BlapEnd (50-GTGGTGCCCTTT
CCCGTTCATGTTTAAGGC-30). PCR fragments .400 bp
conﬁrmed the presence of an insert into blaP.
Bio-panning procedure. The afﬁnity selection of the phage
library was achieved against the CAT-8015-related mono-
clonal antibody (mAb 8015). The rabbit monoclonal anti-
body anti-CD22 provided by Epitomics (mAb EP498Y),
which recognises the 20 N-terminus amino acids of the
CD22 (DSSKWVFEHPETLYAWEGAC), was chosen as a
control for linear epitope selection. Five hundred nanograms
of mAb 8015 and 200 ng of mAb EP498Y diluted in carbon-
ate buffer (50 mM NaHCO3, pH 9.6) were coated onto
Maxisorp
w microplate strips (Nalgen Nunc International) for
16 h at 48C. After washing with Tween/TBS (Tris Buffered
Saline with 0.05 % Tween 20), the wells were blocked with
BSA 1% in TTBS for 1 h at 378C and washed again with
TTBS. Then 10
12 phage particles were added per well and
incubated overnight at 48C. Unbound phages were removed
by successive washings with TTBS and bound phages were
eluted in 25-mM glycine–HCl buffer (pH 2.2) for 5 min.
The eluate was transferred to a tube and neutralised with 2 M
Tris–HCl (pH 8). The eluted phages were ampliﬁed by
infecting log phase E.coli TG1.
Phage ELISA. The analysis of the binding properties of
phage was performed as described for the bio-panning pro-
cedure except that elution step was replaced by the addition
of a colorimetric substrate. The immobilised b-lactamase
activity carried by phage was measured by following the
hydrolysis of 100 mM nitroceﬁn in 50 mM phosphate buffer
pH 7.5 at 482 nm.
Epitope-array methodology
Construction of oligonucleotide microarray. The CD22ed
oligonucleotide microarray was designed using 72 non-
overlapping oligonucleotides that cover the whole sequence
coding for the extracellular domain. Each oligonucleotide
was spotted in duplicate. The microarrays were printed by
Eurogentec using the VersArray
w ChipWriter Pro System
(Bio-Rad). Positive control oligonucleotides, complementary
to BlaP sequences upstream and downstream of the insertion
site, were included as well as mismatched controls (90, 80
and 60% of mismatch) to monitor washing steps and hybrid-
isation speciﬁcity.
Probe preparation. Fluorescent DNA probes were prepared
from initial and enriched phage libraries by PCR ampliﬁca-
tion using Taq polymerase with primers BlapSmaseq and
BlapEnd. The probes were labelled with Cy3-dCTP (GE
Healthcare).
Hybridisation and washing. Fluorescent probe mixtures were
diluted in the hybridisation buffer provided by Eurogentec
and added with calf thymus DNA (Sigma). Fluorescent
probe mixtures were denatured at 958C for 5 min, and
applied onto the chip under a cover glass. Chips were hybri-
dised at 428C for 16–18 h. The hybridised chips were then
washed at room temperature successively with the washing
buffer 1 (30-mM NaCl, 3-mM sodium citrate, 0.1% SDS, pH
7) and the washing buffer 2 (30-mM NaCl, 3-mM Sodium
citrate, pH 7). The chips were dried at room temperature
before scanning.
Detection and analysis. The chips were scanned with a
GenePix 4000A ﬂuorescence reader (Axon) to detect emis-
sion from the Cy3 label at 650 nm, following laser excitation
at 550 nm. The acquired images were analysed by GenePix
Pro analysis software (Axon).
Modelling of CD22
The C-type domains 2–3 of CD22 were modelled separ-
ately. The MODELER program in Accelrys Discovery
Studio software package was used for modelling these
domains. The intervening sequences between the domains
were also included in the modelling. The model of carci-
noembryonic antigen (CEA) which consists of seven extra-
cellular Ig-like domains similar to that predicted for CD22
was used as the structural template for assembling the
modelled domains. Alternative orientations of the C-type
domains 2 and 3 were also modelled based on the struc-
tures of either human Fcg receptor (2fcb) or leukocyte
Ig-like receptor A5 (2d3v). Models were subject to energy
minimisation with CHARMm forceﬁeld in the Accelrys
Discovery Studio package.
Analysis of CD22 sub-domain binding
Expression and puriﬁcation of the CD22 sub-domain V234–
G435 into BlaP. Gene-fragments coding for the native and
the 36 single-alanine mutants of the CD22 sub-domain
(V234–G435) were chemically synthesised and cloned into
the permissive SmaI insertion site of BlaP carried by the
pNY vector (Chevigne et al., 2007). pNY allows E.coli full
constitutive expression of BlaP. The nucleotidic sequence of
the hybrid genes were veriﬁed by dideoxy sequencing. To
achieve production of the BlaP CD22 hybrid proteins, E.coli
BL21 transformed with the pNY derivative plasmids was
grown in Terriﬁc Broth supplemented with 75 mg/ml
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an overnight culture (500 ml) were harvested by centrifu-
gation (9000 g for 15 min).
The periplasmic proteins were harvested by a cold shock
osmotic procedure using a successive treatment of cells
with TES (20% sucrose, 30-Tris–HCl, 5-EDTA, pH 8)
and 5-MgSO4. The periplasmic proteins were puriﬁed on the
automated Proﬁnia Imac puriﬁcation system (Bio-rad) using
the preprogrammed method. The eluted proteins were condi-
tionned in PBS (50-mM phosphate, 150-mM NaCl, pH 7.5).
Comparative-binding assays. Two distinct procedures were
used to compare the binding activity of the BlaP CD22
hybrid proteins to mAb 8015. In the ﬁrst procedure, 100 ng
of monoclonal antibody diluted in carbonate buffer were
coated for 16 h at 48C onto Maxisorp
w microplate strips
(Nalge Nunc International). After washing with PBST (PBS
with 0.05% tween 20), wells were blocked with 2% BSA in
PBST for 1 h at 378C. Native and mutated CD22 sub-
domains displayed within the HIS-tagged BlaP b-lactamase
were incubated upon the immobilised antibody for 2 h at RT.
After washing with PBS, anti-polyhistidine HRP-conjugate
(Roche) was diluted in PBS (1/2500) and incubated in the
wells for 1 h at 378C. Unbound antibodies were removed by
washes with PBS. ABTS [2,20-azinobis(3-ethylbenzthiazo-
line-6-sulfonic acid)] (0.2 mg/ml ﬁnal) in 50 mM citric acid
(pH 4) was used as substrate to measure captured peroxidase
activity at 405 nm.
In the second procedure, ELISA was carried out on
HIS-Select
w High Sensitivity Nickel Coated Microplates
(Sigma). Five hundred nanograms of BlaP CD22 hybrid pro-
teins diluted in PBS were coated for 16 h at 48C. After
washing with PBST (PBS with 0.05% Tween 20), wells were
blocked with 2% BSA in PBST for 1 h at 378C. Bound
hybrid protein was detected with 100 ng of mAb 8015
diluted in PBS for 1 h at 378C. Unbound mAb 8015 were
removed by several washes with PBS. Anti-human HRP con-
jugate (Promega) was diluted in PBS (1/2500) and incubated
in the wells for 1 h at 378C. Unbound antibodies were
removed by washes with PBS and ABTS was used as sub-
strate to measure captured peroxidase activity.
In order to take into account the non-speciﬁc binding, data
were adjusted by subtracting the non-speciﬁc binding value
of an irrelevant antibody from the mean binding score, fol-
lowing the formula: binding of BlaP CD22/C2C3 mutant ¼
(mean binding score of BlaP CD22/C2C3 mutant to mAb
8015 – mean binding score of BlaP CD22/C2C3 mutant to
irrelevant mAb).
Then data were normalised to the average-binding score of
the wild-type strain in order to have a reference level at 100
for the wild-type strain: normalised binding of BlaP CD22/
C2C3 mutant ¼ binding of BlaP CD22/C2C3 mutant/binding
of BlaP CD22/C2C3 WT   100.
Data were analysed by the software package R (Chambers,
2008) using a two-way ANOVA considering strain and
experiment as factors. Pairwise differences between strains
were then obtained with the Tukey’s method (Honest signiﬁ-
cant difference). This method tests the difference between
factor levels, while adjusting P-values in order to control the
family-wise error rate that inﬂates in the case of multiple
comparisons.
Dissociation constant measurements. The dissociation con-
stant (Kd) of the BlaP CD22–mAb 8015 complex was deter-
mined according to the previous ELISA (Friguet et al.,
1985). The BlaP CD22 concentrations that yielded a linear
signal with 1 mg of coated mAb 8015 were determined by
following the immobilised b-lactamase activity as described
above. In the assays, the percentage of BlaP CD22 bound to
the immobilised mAb 8015 was below 2.5% of the total
amount of hybrid protein added in the well to avoid modiﬁ-
cation of the equilibrium in solution. To determine the Kd,
various concentrations of free mAb 8015 were preincubated
with BlaP CD22. After the equilibrium was reached (1 h at
room temperature), the concentration of free BlaP CD22 in
each sample was determined with the help of mAb
8015-coated microplates as described above. The
b-lactamase activities were plotted versus the concentration
of free mAb 8015 mixed to BlaP CD22. The titration curve
obeys the following equation:
A2½E 0 þ AðA0½L 0 þ A0Kd   A0½E 0Þ A2
0Kd ¼ 0;
where [E]0 and [L]0 are the initial concentrations of BlaP
CD22 and the total concentration of mAb 8015 in solution,
respectively; Kd is the dissociation constant; A0 and A are
the activities measured on coated mAb 8015 before or after
preincubation with mAb 8015, respectively. The Kd was
deduced by ﬁtting the experimental points to the equation
given above.
Results
Isolation of minimal CD22 sub-regions conferring high
afﬁnity to mAb 8015
Although previous studies using antibody competition assays
suggested that RFB4, the parent antibody of CAT-8015,
bound to the C-like domain 2 region, the entire extracellular
domain of CD22 (Supplementary data, Fig. 1) was chosen as
a starting point to construct the CD22 gene-fragment phage
library. Following gene fragmentation and cloning, 6   10
5
transformants were obtained and a PCR analysis indicated
that more than 95% of the clones were positive for the pres-
ence of a CD22 gene fragment in blaP and that the size dis-
tribution of the inserts was from 50 bp up to 1000 bp.
Epitope-array analysis conﬁrmed that the entire CD22 gene
was well represented in the b-lactamase positive infectious
phage library except for two small regions encoding the
short amino acid sequences WKPHGAW and PETIGRR
(data not shown). The lower representation of these regions
could be due to a lower permissivity into the carrier protein,
to an unexpected mis-hybridation or even more to an insufﬁ-
cient spotting.
The phage library was afﬁnity enriched on two distinct
monoclonal antibodies, mAb 8015 and mAb EP498Y. The
mAb EP498Y was used as a control to monitor the efﬁciency
of the bio-panning procedure to identify a linear epitope.
After three rounds of bio-panning, the binding properties of
both enriched phage libraries were analysed by measuring
the immobilised b-lactamase activity on the coated mAbs.
Figure 1 shows that both libraries have been speciﬁcally
enriched with hybrid b-lactamases displaying a speciﬁc
binding activity against their related mAb. The epitope-arrays
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enriched upon mAb EP498Y and mAb 8015 have diverged
during the successive rounds of bio-panning.
According to the results, the protein region mapped with
mAb EP498Y (region 1) corresponds to the N-terminus of
CD22 reported from the mAb provider and does not overlap
with the two protein regions identiﬁed with mAb 8015. With
mAb EP498Y, the highest signal was obtained on oligonu-
cleotide 1 suggesting that the peptide sequence
DSSKWVFEHP is of crucial importance for the binding of
the antibody (region 1 of Fig. 2A).
Of the two regions highlighted in the epitope-array as
being important for mAb 8015 binding (Fig. 2B), region 3
has higher overall ﬂuorescence intensity, suggesting that the
contribution of region 3 is more important for the binding
activity. This region also includes the C-type domain 2 pre-
viously deﬁned as relevant for the binding to RFB4.
Selection of a relevant hybrid b-lactamase for studying mAb
8015-binding properties
To identify the most appropriate hybrid b-lactamase for con-
ducting the characteriation of mAb 8015, we performed PCR
and phage ELISA analysis on single clones (Fig. 3A). Phage
ELISA was used to conﬁrm that the selected clones express a
hybrid protein that displays a CD22 fragment able to interact
strongly and speciﬁcally with mAb 8015. From these exper-
iments, 14 candidates were selected and sequenced. The
multiple sequence alignment (Fig. 3B) suggested that the
minimal region conferring high afﬁnity for mAb 8015
encompasses a region of 202 residues in length (V234–
G435) that includes the C-terminal amino acids of the
C-type domain 1, the whole of C-type domains 2 and 3 and
the N-terminal amino acids of the C-type domain 4. Further
truncation of this fragment resulted in signiﬁcant reduction
in binding to mAb 8015 (data not shown). The hybrid
b-lactamase displaying this fragment (BlaP CD22/C2C3)
was overexpressed in E.coli and puriﬁed by afﬁnity chrom-
atography. The graphs presented in Fig. 4 show that this
hybrid protein binds speciﬁcally to mAb 8015 (Fig. 4A) with
a Kd calculated to 26.2+1.4 nM, that free mAb 8015 com-
petes with the coated mAb 8015 for binding to BlaP CD22/
C2C3 (Fig. 4B) and that the CD22 antibody epratuzumab
does not share the same epitope (Fig. 4C).
Alanine-scanning analysis
To investigate the interaction network of the complex
between CD22 and mAb8015, we used molecular modelling
to ﬁrst identify residues in the CD22 fragment (V234–G435)
displayed within the BlaP CD22/C2C3 construct that would
be predicted to have some degree of solvent accessibility.
From this study, 36 residues were chosen to perform single-
point mutation to alanine. As shown in Fig. 5, these
mutations form three clusters: cluster 1 (Q235-I246) is
located in the junction between the C-type domains 1 and 2,
cluster 2 (G375-P388) is in the C-type domain 3 and cluster
3 (P418-R433) encompasses both the junction between the
C-type domains 3 and 4, and the N-terminal part of the
C-type domain 4. Among 36 mutated hybrid proteins, only
two were not expressed due to recurrent sequence deletion
located after the substituted residue. The 34 active mutants
were overexpressed in E.coli and puriﬁed by afﬁnity
chromatography.
The binding activity of each mutant to mAb 8015 was
measured by ELISA and compared with the binding of the
wild-type BlaP CD22/C2C3 protein. Statistical analysis of
the data showed that the experiments were highly correlated
and that the residual afﬁnities measured with both procedures
did not differ signiﬁcantly from each other (data not shown).
Figure 5 shows the mutation effects ordered by a decreasing
binding. From this statistical analysis, it appears that the
BlaP CD22/C2C3 mutants corresponding to L236A, H240A,
R376A and K385A are not signiﬁcantly different from the
wild-type at a family-wise error of 5% while the BlaP CD22/
C2C3 mutants corresponding to P242A, K243A and I246A
cause the most drastic effect on binding to mAb 8015. The
other mutants can be classiﬁed in two intermediate groups
depending on whether the mutation has minor or important
impact on the binding. Considering the 13 mutations that
have a percentage of residual binding below 50%, 4/13 corre-
spond to proline (P242, P384, P388 and P431), 4/13 are
charged residues (K239, K243, E378 and R433), 4/13 are
non-polar residues (I246, G375, I383 and M430) and only
one residue is a polar residue with a neutral side chain
(T377).
Modelling of CD22
The C-type domains 2 and 3 of CD22, which contained the
mAb 8015 epitope clusters 1 and 2 were modelled separately
based on homologies to the C2-type domain 3 of human
Fig. 1 Phage ELISA performed with the phage libraries obtained after three
rounds of panning on mAb 8015 and mAb EP498Y. (A) Phage ELISA
performed with the mAb EP498Y-enriched library. Two hundred nanograms
of mAb EP498Y was coated in the assays. (B) Phage ELISA performed with
the mAb 8015-enriched library. Two hundred nanograms of mAb 8015 was
coated in the assays. Nitroceﬁn (100 mM) was used as substrate. The mAb
anti-HA (200 ng per well) was used as a control for non-speciﬁc-binding
activity.
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domain of human TAG-1 (2om5, Mortl et al., 2007), respect-
ively. The separate models were then assembled together in
different orientations based on the solved structures of other
multi-domain Ig-like proteins, carcinoembryonic antigen
(Fig. 6A), human Fcg-receptor (Fig. 6B) and leukocyte
Ig-like receptor A5 (Fig. 6C). Ramachandran plot statistics
showed the ﬁnal models were of acceptable quality (89.6%
of residues in allowed region; 9.5% in generously allowed
region; 0.9% in the disallowed region). The domain arrange-
ments based on human Fcg-receptor and leukocyte Ig-like
receptor A5 resulted in a shorter distance (30–36 A ˚)
between the two epitope clusters than the linear arrangement
based on carcinoembryonic antigen, where the distance
between epitope clusters was 60 A ˚.
Discussion
CAT-8015 is an immunotoxin of signiﬁcant clinical inter-
est, which has shown activity in both CLL and HCL
patients. This drug exerts its effect via binding to CD22
and consequent, rapid internalisation into target cancer
cells to deliver the toxic component PE38. It has pre-
viously been shown by antibody competition binding
studies that antibody RFB4, the parent of CAT-8015, is
likely to bind an epitope in the C-type domain 2 of CD22.
However, as antibody competition assays can provide
imprecise epitope locations, this study was performed using
the hybrid b-lactamase technology. This new approach was
applied in order to isolate from a b-lactamase displaying
CD22 fragment library the minimal sub-region of CD22 that is
able to be bound efﬁciently by mAb 8015, to produce it as a
soluble hybrid protein carrying an enzymatic reporting activity
and to use this ‘antigen-like’ material for characterising the
CD22/mAb 8015 interaction. The aim of this work was to
understand whether the epitope of CAT-8015 had unique prop-
erties, which may confer its ability to rapidly internalise and
deliver toxins into target cells.
The mAb 8015 was obtained by afﬁnity maturation of
mAb RFB4 resulting in a high-afﬁnity monoclonal antibody
with a dissociation constant (Kd) below the nanomolar range
(Ho et al., 2005). Such afﬁnity gains are generally associated
with mutations that make the interaction between the anti-
body paratope and the antigen epitope more energetically
stable or create new interaction sites. As a consequence, the
mean surface area between an antibody variable domain and
its antigen is 600–800 A ˚ 2 allowing the establishment of a
large network of interactions.
The complexity of the interaction between mAb 8015 and
CD22 was conﬁrmed by our results since the minimal sub-
region of CD22 conferring high afﬁnity for mAb 8015
encompasses a 202 residue protein fragment (V234–G435)
including the whole of C-type domains 2 and 3. Selection of
smaller fragments failed, suggesting that the most important
structural elements required for the binding to mAb 8015 are
present in the CD22 sub-domain V234–G435. The large size
of this fragment suggests that the mAb 8015-related epitope
is discontinuous and that both the C-type domains 2 and 3,
and possibly their junction regions, play a role in the for-
mation of this epitope. Interestingly, the present study has
highlighted a greater level of epitope complexity than pre-
viously reported. It was suggested from previous antibody
competition and CD22 domain deletion studies that both
mAb 8015 and epratuzumab bound to the C-like domain 2
whereas here we show that the mAb 8015 epitope encom-
passes regions of both C-like domains 2 and 3 and further
that epratuzumab is unable to bind to the same CD22
fragment.
To investigate the binding properties of mAb 8015, we
overexpressed and puriﬁed the CD22 sub-domain V234–
Fig. 2 Epitope-arrays performed with the phage libraries obtained after three rounds of panning with mAb EP498Y (A) and mAb 8015 (B). The arrays,
consisting of 72 oligonucleotides spanning the nucleotide sequence of the extracellular portion of CD22, were probed with ﬂuorescently labelled PCR products
from the round three phage selection outputs. Hybridisation controls UP and RP are positive controls for labelling and library ampliﬁcation, which are
complementary to BlaP sequences upstream and downstream the insertion site. T7 and surrounders bars are mismatched UP controls (90, 80 and 60% of
mismatch) used to monitor washing steps and hybridisation speciﬁcity. (C) Representation of regions 1, 2 and 3 on the primary amino acid sequence of human
CD22.
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356G435 as a soluble hybrid protein. The implementation of this
bifunctional protein in immunoassays enabled us to conﬁrm
the speciﬁcity of the interaction with mAb 8015 by using the
b-lactamase enzyme as a reporting activity. It is worth
acknowledging that the 26-nM afﬁnity observed with the
CD22 sub-domain was lower than that for the entire CD22
extracellular region, previously reported as 0.8 nM (Ho et al.,
2005). This suggests that some element of the native epitope
could be missing in the CD22 minimal epitope fragment
inserted within the BlaP. For instance, this could be the case
if we consider that region 2 depicted on Fig. 3B, which
resides in C-type domain 1 and is not included in the sub-
domain V234–G435, also plays a minor role in the binding
upon mAb 8015. Another explanation could be due to steric
hindrance, whereby the b-lactamase protein carrier obstructs
the epitope, or a subtle structural modiﬁcation that affects the
reconstituted epitope. A more mundane explanation could be
that the method used previously to determine afﬁnity, which
was a saturation binding analysis on cells (Ho et al., 2005),
was substantially different from the method employed here,
which used recombinant antigen.
To reﬁne the mapping of the mAb 8015-related epitope,
we submitted the hybrid protein to an alanine-scanning
study. From this experiment, we concluded that residues in
three distinct epitope clusters have an important impact on
the mAb binding. Considering only the point mutations
giving a percentage of residual binding below 50% of wild
type, we observed that the key residues in clusters 1, 2 and 3
are (K239/P242/K243/I246), (G375/T377/E378/I383/P384/
P388) and (M430/P431/R432), respectively. Most of the key
residues map to clusters 1 and 2, located in the C-type
domains 2 and 3, respectively, and the modelling of different
orientations of these two domains strongly suggested that a
U-shaped arrangement of these domains would bring the
clusters into close enough proximity to form an antibody
epitope. The distance between clusters of 30–36 A ˚ would be
broadly in line with a total surface interaction area of
between 600 and 800 A ˚ 2, typical for discontinuous antibody
epitopes. Although cluster 3 could not be included in the
model due to the lack of a suitable template structure in that
region, we hypothesise that the U-shaped arrangement would
also bring cluster 3 into close enough proximity to be
Fig. 3 Isolation of a hybrid protein, comprising beta-lactamase with a CD22 fragment insertion, for conducting the mutational analysis. (A) Phage ELISA of
different hybrid proteins performed on 200 ng of coated mAb 8015 with supernatants of isolated phage culture. Nitroceﬁn (100 mM) was used as reporter
substrate. (B) Multiple sequence alignment of the 14 candidates selected in (A).
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357incorporated into the mAb 8015 epitope (Fig. 7).
Encouragingly, there is some precedent for other Ig-like pro-
teins, such as the neural cell adhesion molecule axonin-1/
TAG-1 (Freigang et al., 2000) and hemolin (Su et al., 1998),
adopting U-shaped forms by incorporating tight turns
between adjacent Ig-like domains. Furthermore, previous
Fig. 4 Binding and competition assays performed with the hybrid b-lactamase containing CD22 residues V234–G435, referred to as the bifunctional hybrid
protein (BHP). (A) Binding assay performed on 200 ng of coated mAb anti-IL6 or mAb 8015 with 130 ng of BHP. (B) Competition assays performed on
200 ng of coated mAb 8015 with 1.3 mg of BHP supplemented with 1.3 mg (1/1), 2.6 mg (1/2) or 7.5 mg (1/5) of free mAb anti-IL6 or free mAb 8015. (C)
Competition assays performed on 100 ng of coated mAb 8015 and mAb epratuzumab with 1.3 mg of BHP supplemented with 1.3 mg (1/1), 2.6 mg (1/2) or
7.5 mg (1/5) of free mAb 8015. Nitroceﬁn (100 mM) was used as reporter substrate.
Fig. 5 Summary of the binding of CD22 fragments (V234–G435), each containing single-alanine substitutions, to CAT-8015 IgG1, normalised to the binding
of the wild-type CD22 fragment. (A) Statistical analysis of the residual binding data according to the ANOVA method allowed grouping into four distinct
groups: coloured red, orange, yellow and green, based on the loss of binding signal as a result of alanine substitution (red, 0–20% residual binding; orange,
20–50% residual binding; yellow, 50–80% residual binding; green, 80–100% residual binding). Results are presented as box-and-whisker plots, with the bold
line representing the median value and boundaries of the box representing the 25th and 75th percentile. The bars represent the data extremes. (B)
Representation of the same residues, with the same colouring scheme, on the amino acid sequence of CD22 fragment (V234–G435).
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358work has shown that the b-lactamase BlaP is a rigid protein
but very permissive to polypeptide, protein fragment or
entire protein insertion. This feature enables the b-lactamase
to keep its structural organisation, which is essential for
enzymatic activity. As the b-lactamase activity of the hybrid
protein BlaP CD22/C2C3 is relatively well conserved (data
Fig. 6 Alternative arrangements of C2 (cyan) and C3 (grey) domains of CD22 obtained by superposition of the models of these domains on (A), a model of
carcinoembryonic antigen (domains 3 and 4; 1e07.pdb), (B) crystal structure of human Fcg-receptor (2fcb.pdb) and (C) crystal structure of leukocyte Ig-like
receptor A5 (2d3v.pdb). Residues mutated to alanine are coloured according to the percentage of wild-type binding to CAT-8015, upon alanine substitution
(red, 0–20% residual binding; orange, 20–50% residual binding; yellow, 50–80% residual binding; green, 80–100% residual binding). Approximate distance
between C-a atoms of I246 in the C2 domain and R376 in the C3 domain are shown as an indication of the proximity of the epitope clusters (cluster 1 at the
top and cluster 2 at the bottom).
Fig. 7 Hypothetical linear and U-shaped arrangements of CD22. The hypothetical linear arrangement results in the epitope clusters being far apart (A),
whereas the hypothetical U-shaped arrangement formed by the C-type domains 1–4 brings the epitope clusters into closer proximity for binding to CAT-8015
and potentially enables cis interactions with sialic acid groups on other cell surface glycoproteins (B). Also shown is a schematic representation of the CD22
fragment (V234–G435) in the context of b-lactamase (C).
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359not shown), we assume that the N- and C-terminal parts of
CD22/C2C3 are quite close to each other into BlaP support-
ing the concept that C-type domains 2 and 3 can adopt a
U-shaped conﬁguration (Fig. 7C).
The hypothesis that some Ig-like domains of CD22 could
interact together to give a more compact structural organis-
ation is consistent with the fact that CD22 is known to inter-
act in cis with sialic acid groups of other B cell
glycoproteins (Razi and Varki, 1998). Using in situ photoafﬁ-
nity cross-linking of glycan ligands to CD22 Han et al.
(2005) observed that CD22 also recognises glycans of neigh-
bouring CD22 molecules as cis ligands, forming homomulti-
meric complexes. It is thought that these cis interactions of
CD22 on the B cell surface play an important role in
masking the sialic acid binding V-like domain and prevent-
ing CD22 from interacting in trans with other carbohydrate
groups. The hypothetical structure (Fig. 7B) suggested by
this study would be consistent with such cis interactions.
In conclusion, the present study has explored the molecu-
lar epitope of the investigational therapeutic immunotoxin
CAT-8015 and shown it to be a complicated structural
arrangement, involving at least three discontinuous regions
of the CD22 polypeptide. Whether or not the same approach
will work for other antigens with contrasting protein struc-
tures requires further epitope mapping studies. However, the
hybrid b-lactamase technology has now been used success-
fully to resolve epitopes of antigens, which do not resemble
the Ig-like domain structure of CD22 (data not shown),
suggesting that the method could be broadly applicable to
different antigen structures. In this example, the technology
allowed the identiﬁcation of the minimal epitope fragment of
CD22, despite its structural complexity, due to b-lactamase
enabling the correct folding of the embedded antigen.
Alanine scanning of this CD22 sub-domain reagent allowed
further deﬁnition of the key-binding residues demonstrating
that this technology is suited to the characterisation of
complex epitopes.
Supplementary data
Supplementary data are available at PEDS online.
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